✦ LIBER ✦

388 POSTER Safety, pharmacokinetics and preliminary activity of the anti-IGF-IR antibody CP-751,871 in patients with sarcoma

✍ Scribed by S. Postel-Vinay; S. Okuno; S. Schuetze; M.L. Paccagnella; D. Yin; A. Gualberto; F. Worden; P. Haluska; J. De Bono; M. Scurr

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Safety, pharmacokinetics, and preliminar

✍ David Olmos; Sophie Postel-Vinay; L Rhoda Molife; Scott H Okuno; Scott M Schuetz 📂 Article 📅 2010 🏛 The Lancet 🌐 English ⚖ 398 KB

1006 The anti-IGF-IR antibody figitumuma

✍ A. Gualberto; M.L. Hixon; M.P. Dolled-Filhart; J. Chistensen; D.L. Rimm; A.V. Le 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 68 KB

565 POSTER Activity of the anti-IGF-IR a

✍ J.S. De Bono; D.P. Petrylak; E. Calvo; F. Saad; G.R. Hudes; M.M. Cooney; M.N. Po 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 69 KB

Safety, tolerability, and pharmacokineti

✍ Paul Haluska; Frank Worden; David Olmos; Donghua Yin; David Schteingart; Gretche 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 425 KB

Safety and pharmacokinetics of the anti-

✍ Martin Bednar; Qinying Zhao; Jaren W. Landen; Clare B. Billing; Kevin Rohrbacher 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 96 KB

1201 ORAL Early Studies of the Safety, P

✍ L. Rosen; P. Munster; S. Bai; P. Hegde; J. Fredrickson; R. Funke; I. Chang; D. C 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 44 KB